CRO startup Vial scores $67M Series B led by General Catalyst

Vial, a CRO specializing in offering clinical trial services to biotech companies, raised $67 million in a new round of funding, bringing its total money raised to $100 million.

The San Francisco-based company’s Series B round was led by General Catalyst and supported others such as Byers Capital and BoxGroup.